GtoPdb Ligand ID: 9758

Synonyms: INCSHR1210 | SHR-1210
camrelizumab is an approved drug (China (2019))
Compound class: Antibody
Comment: Camrelizumab is a fully human anti-programmed cell death 1 (PD-1) monoclonal antibody being developed as an immuno-oncology therapeutic.

SARS-CoV-2 and COVID-19: Clinical efficacy of camrelizumab plus thymosin in patients with COVID-19 will be evaluated in clinical trial NCT04268537.
Compound class Antibody
Approved drug? Yes (China (2019))
International Nonproprietary Names
INN number INN
10400 camrelizumab
INCSHR1210 | SHR-1210
Database Links
Specialist databases
IMGT/mAb-DB 659
Other databases
GtoPdb PubChem SID 354702231
Search PubMed clinical trials camrelizumab
Search PubMed titles camrelizumab
Search PubMed titles/abstracts camrelizumab